RESPIRATORIUS AB
NNGM:RESP1.93
SEK
-0.02
(-1.28%)
ISIN
SE0023314315
Return %
Stock
S&P 500
1Y
-23.11
14.20
3Y
-90.69
81.12
5Y
-98.23
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Johan Drott
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lund Sweden
- IPO Date
- Jul 5, 2012
- Website
- respiratorius.com
- Similar Companies
- Business
- Respiratorius AB (publ) is a Sweden-based clinical-stage biopharmaceutical company that discovers and develops innovative pharmaceutical candidates for the treatment of oncology and chronic respiratory diseases. Founded in 1999 and headquartered in Lund, Sweden, the company operates within the biotechnology and life sciences industry, focusing on advancing drug candidates from discovery and preclinical phases through clinical proof-of-concept before securing out-licensing partnerships with global pharmaceutical companies for Phase III clinical development and worldwide commercialization. The company's core product development pipeline includes: VAL001, a proprietary oral formulation combining sodium valproate and standard chemotherapy pre-treatment developed for patients suffering from diffuse large B-cell lymphoma (DLBCL), which has demonstrated improved overall survival in Phase I/IIa clinical trials and holds orphan drug designations from both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA); the RESP-9000 series, a portfolio of small molecule drug candidates with dual bronchodilatory and anti-inflammatory mechanisms of action designed for the treatment of chronic obstructive pulmonary disease (COPD) and severe asthma; and the RESP-3000 series, an exploratory series of preclinical compounds targeting inflammatory pathways in respiratory and cardiovascular diseases. In recent developments, Respiratorius AB has focused on global partnering and licensing activities for its lead candidate VAL001, having finalized pharmacokinetic and formulation studies to establish a commercially scalable oral formulation in preparation for Phase III clinical trials. The company has secured broad international patent protections covering the novel formulation and therapeutic applications of VAL001 across key markets, including the United States, Europe, and Japan. Additionally, Respiratorius has advanced preclinical validation for its RESP-9000 series to strengthen partnering packages and completed targeted financing rounds to support ongoing regulatory consultations, intellectual property maintenance, and business development operations.